We have reported the identification of human gene MAGE-1, which directs the expression of an antigen recognized on a melanoma by autologous cytolytic T lymphocytes (CTL). We show here that CTL directed against this antigen, which was named MZ2-E, recognize a nonapeptide encoded by the third exon of gene MAGE-1 . The CTL also recognize this peptide when it is presented by mouse cells transfected with an HLA-A1 gene, confirming the association of antigen MZ2-E with the HLAA1 molecule. Other members of the MAGE gene family do not code for the same peptide, suggesting that only MAGE-1 produces the antigen recognized by the anti-MZ2-E CTL . Our results open the possibility of immunizing HLAA1 patients whose tumor expresses MAGE-1 either with the antigenic peptide or with autologous antigen-presenting cells pulsed with the peptide .
ixed lymphocyte-tumor cell cultures carried out with human melanoma cells and lymphocytes of the same patient often generate CTL that lyse the autologous tumor cells (1) (2) (3) (4) . Using blood lymphocytes of melanoma patient MZ2, we have obtained a panel of CD8+ CTL clones that lyse the autologous tumor cell line MZ2-MEL (3) . Antigenloss variants of MZ2-MEL were obtained by selecting tumor cells that were resistant to some of these CTL clones . The pattern of resistance of these antigen-loss variants demonstrated that six different antigens are recognized on the tumor cells by the autologous CTL (5) . To identify the gene of one of these antigens, which was named MZ2-E (E), a cosmid library prepared with the DNA of a MZ2-MEL subclone was transfected into E -antigen-loss variant MZ2-MEL .2.2. This led to the isolation of gene MAGE-1, which directs the expression of antigen MZ2-E (6, 7) . The gene was found to be deleted in the antigen-loss variant .
Gene MAGE-1 comprises three exons. A large open reading frame is entirely contained in the third exon. The sequence of the gene found in normal cells of the patient appears to be identical to that found in the melanoma cells . The gene does not appear to be expressed in normal tissues, but it is expressed in -40% of the melanoma cell lines and tumor samples that have been analyzed (8) .
Gene MAGE-1 belongs to a family of several closely related genes . Melanoma MZ2-MEL expresses, in addition to MAGE-1, two other members of this family, called MAGE-2 and MAGE-3. These two genes do not direct the expression of antigen MZ2-E . Like MAGE-1, they do not appear to be expressed in normal tissues.
There is now overwhelming evidence that CD8+ CTL recognize their antigen in the form of a small peptide bound to a class I MHC molecule (9-11) . This implies that each MAGE gene expressed in tumor cells could provide one or more peptides binding to some class I molecule, thus providing a tumor-specific antigen . As a first step in the analysis of these potential antigens, we report here the identification of a MAGE-1-encoded nonapeptide that combines with HLA-A1 to form antigen MZ2-E . subline MZ2-MEL.2 .2 was selected from subclone MZ2-MEL.3 .1 with an autologous CTL clone (5). Anti-MZ2-E autologous CTL clone 82/30 and its culture conditions have been described elsewhere (6) . Mouse cell line PLHTR was derived from mastocytoma P815 (12) . P1 .HTR was cotransfected with an HLA-A1 gene (13), inserted in expression vector pcD-SRa (14), and with pSVtkneoO (15) . The neon transfectants were cloned and tested for HLA class I expression by flow cytometry using F(ab')2 fragments of mAb B.9 .12.1 (16) . One of these clones expressing HLA class I was then cotransfected with a MAGE-1 cDNA, inserted in expression vector pcD-SRa, and with pHMR272 (17) . The hygromycin-resistant transfectants were cloned and tested for the expression of antigen MZ2-E on the basis of their ability to stimulate the production of TNF by CTL 82/30 (6) .
Cloning of Subgenic Fragments of Gene MAGE-1 . The 2.4-kb BamHI fragment containing exons 2 and 3 of gene MAGE-1 and smaller parts of this fragment were cloned in plasmid vector pTZ18R (19) to evaluate the presence of TNF. The mortality of WEHI cells was estimated 24 h later in a MTT colorimetric assay (6, 20) .
Antigenic Peptides and CTL Assay. Peptides were synthesized on solid phase using F-moc for transient NH 2-terminal protection as described by Atherton et al . (21) , purified by C-18 reverse-phase HPLC, and characterized by amino acid analysis. Lysis of target cells by CTL was tested by chromium release as previously described (22) . In the peptide sensitization assay, 1,000 "Cr-labeled Etarget cells were incubated in 96-well microplates in the presence pSVtkneoo into the E-line, and the geneticin-resistant population was tested for its ability to stimulate TNF release by autologous anti-E CTL clone 82/30 (6) . Thus, we identified a 300-bp fragment of exon 3 that was capable of transferring efficiently the expression of antigen MZ2-E . In agreement with the results obtained with several mouse genes (23, (25) (26) (27) , this fragment was located in the large open reading frame of gene MAGE-1 (Fig. 1) . The Antigenic Peptide. In the search for potential peptide sequences, we focused on those parts of the 300-bp fragment where the MAGE-1 amino acid sequence differs from that of MAGE-2 and -3. This was based on the observation that genes MAGE-2 and -3 do not direct the expression of antigen MZ2-E . Several 15-amino acid peptides were synthesized . Sensitization of E-cells to lysis by the anti-E CTL was observed with a peptide that corresponds to codons 158-172 of the large open reading frame of MAGE-1. Shorter peptides were prepared, and efficient lysis of E-cells was observed with nonapeptide EADPTGHSY (codons 161-169) (Figs . 2 and 3 ) . Half-maximal lysis was obtained at a peptide concentration of 5 nM (Fig . 2) . In agreement with the evidence that most peptides recovered from MHC class I molecules are nonapeptides (11), we found that the removal of either the NH2-terminal Glu or the COOH-terminal Tyr abolished the ability of the peptide to sensitize cells to lysis (Fig. 2) .
Presentation of the Peptide L . HLAA1. Previous experiments involving the transfection of gene MAGE-1 into tumor cells of various haplotypes suggested that HLAA1 was the presenting molecule of antigen MZ2-E (7) . To definitively prove this point, we transfected an HLA-A1 gene (13) into P1 .HTR, a highly transfectable variant derived from mouse tumor cell line P815. When these P1.HTR.A1 cells were incubated in the presence of the MZ2-E nonapeptide, they were lysed by the anti-MZ2-E CTL (Fig. 3) , as were P1.HTR.A1 cells transfected with a MAGE-1 cDNA, indicating that the MZ2-E peptide can be produced and transported in these mouse cells (Fig. 3) . 
Discussion
To our best knowledge, only one other HLA-A1 binding peptide has been identified so far. This is a 13-amino acid peptide corresponding to residues 89-101 of the influenza A nucleoprotein (28) . The sequence of this peptide (PKK-TGGPIYKRVD) shows no obvious similarity with the MZ2-E peptide, except possibly for the Gly and Tyr residues at positions 6 and 9 of the MZ2-E peptide . The COOH-terminal Tyr may serve as anchoring residue, as reported for Kd-and Kb-restricted antigenic peptides (29, 30) .
Because MAGE-1 belongs to a family of several highly related genes, it was of interest to compare these genes in the region that is homologous to the region of MAGE-1 that codes for the MZ2-E peptide. As shown in Fig. 4 , other MAGE genes code for peptides that are not identical to the MZ2-E 
peptide. It is therefore likely that none of these genes codes for the antigen recognized by the CTL directed against MZ2-E.
In agreement with this, we have observed that HLA-Al cells expressing one or several of the genes MAGE-2, MAGE-3, and MAGE-4 are not recognized by the anti-E CTL. The conservation of the terminal Glu and Tyr in all the peptides displayed in Fig. 4 is worth noting. Preliminary experiments carried out with some of these peptides containing terminal Glu and Tyr residues failed to compete with the MZ2-E peptide for sensitization to the anti-E CTL. This suggests that binding to HLAAl requires more than these two constant residues. The availability of a gene encoding a tumor antigen recognized by CTL provides the possibility of selecting for imReferences We thank Dr. N. Girdlestone for providing an HLA-Al gene. munization against this antigen for those patients whose tumor expresses the antigen. For antigen MZ2-E, these are HLA-Al patients whose tumor expresses MAGE-1 . These patients can be identified by HLA typing and PCR analysis of the messenger RNA of a small tumor fragment (7) . We expect that -10% of the melanoma patients bear a tumor that expresses the antigen, since MAGE-1 is expressed in 40% of the melanoma tumors, and since the HLA-Al allele is present in 26% of the Caucasian population. Attempts will be made to immunize these patients with irradiated cells expressing antigen MZ2-E. The availability of the antigenic peptide opens new possibilities for immunization, since effective priming of CTL has been reported in mouse systems after immunization with peptides or with presenting cells pulsed with peptides (31) (32) (33) (34) (35) (36) .
